Clinigence Holdings (NUTX) has released an update to notify the public and investors about an entry into a material definitive agreement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Nutex Health Inc. has entered into a Securities Purchase Agreement with a healthcare-focused institutional investor to sell 66,666,666 shares of common stock and equal number of warrants, with the shares and warrants both priced at $0.15. The expected closing date is January 25, 2024, with the warrants exercisable immediately and expiring five years later. The exercise of the warrants is limited to ensure the investor does not surpass a certain ownership threshold. The proceeds, estimated at $10 million before fees and expenses, are intended for working capital, development of facilities and general corporate purposes. The offering is made under a shelf registration statement, and the company has also entered into a placement agency agreement with Maxim Group LLC, agreeing to pay them 7% of the gross proceeds and reimbursement for certain legal fees and expenses.
For further insights into NUTX stock, check out TipRanks’ Stock Analysis page.
